Abstract
Introduction
Alzheimer's disease (AD) is a slowly progressing neurodegenerative disease that leads to dementia [1] . Pathologically, neuron loss and synapse loss occur and provide a neuropathological correlative for dementia [2] [3] [4] . The histopathological hallmarks that characterize AD are senile plaques, neurofibrillary tangles (NFTs) and neuropil threads (NTs) [1, 5, 6] (Fig. 1) .
NFTs and NTs consist of abnormally phosphorylated -protein that aggregates to paired-helical filaments forming neurofibrillary material [7] [8] [9] [10] . These aggregates occur in the soma of nerve cells (NFTs) as well as in neurites (NTs) [1, 7, 8] (Fig. 1) . Tanglebearing neurons degenerate during a number of years resulting in neuronal death [8, 11, 12] . The first step in this process is the occurrence of abnormally phosphorylated -protein in the cell soma of nerve cells before aggregation and tangle formation [8] . 'Tombstone'-tangles are NFTs remaining in the neuropil after neuronal death [5] . [20] . Three stages of CAA can be distinguished (Fig. 2B , Table 1 ) and correlate with the phases of A␤-plaque-deposition and the degree of dementia (Fig. 3C) [20] ). [17, 21, 22] . The amount of A␤-deposition in a given cortical or hippocampal region, i.e. the A␤-load or semiquantitative plaque scores obtained in these regions, does not show significant differences among different degrees of dementia [23] [24] [25] [26] , between control cases with high amounts of AD-related pathology and AD cases [27] [28] [29] [30] [31] and among the levels of brain atrophy [32] . However, when comparing all non-demented cases with AD patients in a sample of 177 elderly autopsy cases between 20 and 99 years of age a significant difference in the A␤-load was observed (Fig. 3D) . [5, 33, 34] 
The deposition of A␤

The deposition of A␤ in the human brain starts in the neocortex and then expands hierarchically into further brain regions representing different phases of A␤-deposition (Fig. 2B, Table 1) [17-19]. These phases of A␤-deposition correlate with the expansion of neurofibrillary changes as represented by the Braak stages (Fig. 2B) [17, 18]. More importantly, the expansion of A␤-deposition into further brain regions also correlates well with the degree of dementia given by the CDR-score similar to that of neurofibrillary tangles as represented by the Braak-stage (Fig. 3A and B) [17]). A similar hierarchical expansion of vascular A␤-deposition was found
Since there is a good correlation between the expansion of A␤-deposition in the brain and dementia it is obvious that the overall distribution of A␤, including diencephalic, brain stem and cerebellar regions, is related to the development of dementia
The deposition of A␤ in different areas of the brain results in the development of different types of A␤-deposits, which can be summarized as amyloid plaques or senile plaques (for review see:
Neurotoxicity of A␤
Synaptic and neuron loss are features of the pathological picture in AD cases [2] [3] [4] [71] . The mutant A␤ peptide showed enhanced oligomerization but no fibrillization [71] [75, 76] and that it can accumulate within neurons [75] . Some of these neurons also showed features of synaptic degeneration [77] and contained oligomeric A␤-aggregates [78] 
Contribution of CAA to the degeneration of neurons
A total of 80-100% of the AD patients exhibit CAA [16, [81] [82] [83] (for review see: [81, 83, 84] [155, 156] and after injection into the brain of -single transgenic mice [157] .
3C). Animal experiments indicated that the phases of A␤-deposition represent a time course of the development of this pathology [33]. Together with the time-dependent degeneration of distinct types of neurons these data strongly suggest that A␤ triggers the process of AD-related neurodegeneration. This hypothesis is strongly supported by the finding that A␤-triggers -pathology in APP--transgenic mice
Pathologically, CAA is characterized by the deposition of A␤ in leptomeningeal, cortical and subcortical cerebral vessels [86] . In addition to arteries and veins capillaries can be affected as well [87] . The deposition of A␤ in the vessel wall leads to destruction of smooth muscle cells in the vessel wall and finally to a fragile vessel wall [88] . In doing so, rupture of such fragile, CAA-affected vessels can cause intracerebral hemorrhage [15, 16, 88] .
A␤ deposition in capillaries distinguishes two types of CAA: CAA-type 1 ϭ CAA with capillary CAA; and CAA-type 2 ϭ CAA without capillary involvement [89] . Other authors suggested that capillary involvement represents most severe CAA but not a distinct type [90] . The strong association of the apolipoprotein E (APOE) 4-allele with the capillary type as well as to the occurrence of capillary CAA in all stages of parenchymal A␤-deposition [89] argue in favour of distinct types of CAA. Recently, CAA-induced capillary occlusion has been found to explain blood flow disturbances in an APP-transgenic mouse model [91] . Moreover, other authors described functional deficits in these mice [92] indicating an affection of those thalamic nuclei, which exhibit capillary CAA with capillary occlusion [91] . Imaging studies revealed that hypoperfusion is well known in the brains of AD patients [93] [94] [95] . In the light of these results CAA-related capillary occlusion is one possible morphological correlative for hypoperfusion. Ischaemic lesions were usually not found near capillary occlusions in human and transgenic mouse brain [91] . However, cerebral infarction is a well-known complication of CAA [15, 16] .
These studies suggest that CAA with capillary occlusion contributes to neuronal dysfunction in AD in addition to direct neurotoxic effects of A␤. This conclusion is supported by the predominant occurrence of capillary CAA (CAA-type 1) in AD cases [83, 90, 96] (Fig. 5) .
Clinical impact of A␤ and its therapeutic possibilities
Since A␤ plays a key role in the pathogenesis of AD and since A␤ is a driving force for neuritic and synaptic degeneration it is a primary target for therapy. Today, blocking A␤-production by ␤-or ␥-secretase inhibition [97] [98] [99] [100] , and active and passive vaccination against A␤ [101] [102] [103] Vaccination strategies are successful in APP-transgenic mice [101] [102] [103] . Both, active and passive vaccination, lead to a reduction of the A␤-load and improve the performance of APP-transgenic mice in cognitive tests [101] [102] [103] . Active vaccination has already been tested in human beings. Although active vaccination leads to a reduction of A␤ in the brain [117] [118] [119] and to a slower progression of cognitive decline [120] severe side effects, i.e. aseptic meningoencephalitis occurred in 6% of the treated patients [121] . There was no evidence so far that A␤-vaccination improved cognition of demented patients [122] . The aseptic meningoencephalitis after A␤-vaccination is a T-cell-mediated inflammatory reaction induced by the dominant T-cell epitope A␤10-24 [123] . The development of vaccines sparing such epitopes appears to be very promising [123] . A further side effect observed after passive immunization in animal models was an increased frequency of hemorrhages due to CAA [124] . An option to avoid such side effects triggered by vascular A␤-deposition could be to start with [158, 159] [122] . In animal models, this therapeutic setting has been shown to be superior compared with beginning at later stages [102] . [12, 17, 19, [125] [126] [127] (Fig. 2B, Table 1 
showed intermediate stages. (D) The A␤-load (obtained as described earlier [44]) in the temporal neocortex was also higher in AD cases than in non-demented individuals with a CDR-score of 0 (n ϭ 177 cases; Student's t-test P < 0.001).
Mean values are presented and the standard deviation is indicated by the bars.
Fig. 4 (A) The frequency of patients with A␤-deposits increases with age. Only 11% of the patients older than 90 years of age were free of A␤-deposits in a sample of 506 autopsy cases. Accordingly, the prevalence of higher phases of A␤-deposition as observed in the medial temporal lobe [18] also increases with age. (B) Similar to the deposition of A␤ NFTs occur in most individuals older than 90 years. In our sample, there was no one free of NFTs at this age. The percentage of cases with NFTs in cases younger than 71 years of age was strikingly higher than that of those with A␤-plaques. This result is in line with previously published samples [48]. (C) In parallel with the increasing frequency of A␤-deposits and NFTs in elderly people CAA occurs more often in advanced ages and the prevalence of higher stages increases when compared with younger age groups. This is demonstrated in a sample of 88 autopsy cases (reproduced with kind permission from [83]).
A␤-vaccination already in asymptomatic patients without CAA
Taken together, vaccination strategies appear to be very promising but this treatment strategy still needs to be successfully tested in human beings for its therapeutic effects and drug safety. As already described above, A␤-deposits occur not only in AD patients but also in cognitively normal individuals [19, 45, 46]. The hierarchical expansion of neurofibrillary and A␤-pathology throughout the brain starts with the first senile plaques in the neocortex and the first NFTs in the transentorhinal region, the basal nucleus of Meynert and the dorsal raphe nucleus in non-demented individuals
). In APP-transgenic mice a similar sequence of A␤-deposition has been reported as in the human brain [33] arguing in favour of the hypothesis that overall A␤-deposition in AD is the end stage of a pathological process starting with the first neocortical plaques. The strong correlation between NFT distribution as represented by the Braakstage and the expansion of A␤-deposition throughout the brain further supports this notion [17]. Following this hypothesis, preclinical AD starts in non-demented patients approximately 20-30 years before the onset of dementia [48, 128] without major neuronal loss. In doing so, these patients with the earliest signs of AD pathology would be the best candidates for a protection from further A␤-toxicity, e.g. by vaccination.
The identification of such early, asymptomatic stages of AD is not possible today before autopsy. However, autopsy studies revealed that initial stages of AD-related pathology prevail in most individuals older than 60 years of age [48] (Fig. 4) . The prevalence of advanced stages of AD-related pathology increases with age [48] (Fig. 4) . The prevalence of end stage AD-related pathology, thereby, correlates with the clinical picture of AD (Fig. 3A-C) . The increase of early stages precedes that of end stages by 20-30 years [48, 128] (Fig. 4) . This demographic prediction strongly underscores the importance to protect people from AD whenever applicable before symptoms arise. [129] [130] [131] . These techniques already allow a good distinction between AD and non-AD patients [129, 130] . The pattern of A␤ detected with these imaging methods is similar to that seen after autopsy [17, 19, 129, [132] [133] [134] . However, reagents like PIB are not specific for binding only on A␤-deposits [135] . Other protein aggregates may cross-react with this dye [135] . Moreover, PIB is a thioflavin S analogue [136] and, in doing so, does not detect all diffuse A␤-deposits that are seen immunohistochemically [134] 
. Extrapolation of the prevalence of AD with increasing life expectancy predicts a dramatic rise of symptomatic AD patients in the future
Imaging techniques using specific markers, e.g. the brain amyloid ligand 11C-labelled Pittsburgh Compound B (PIB), have been developed to detect A␤ in the brain
. Therefore, today it is not possible to identify clinically normal patients with A␤-plaques with these imaging techniques in a sensitive and specific manner but one may expect that such techniques will be improved during the next years allowing a much more sensitive detection of A␤-plaques in the future even in non-demented individuals.
Genetic effects on A␤-deposition are numerous [137, 138] . However, only four genes are widely proven for their influence on AD pathology: APP, PS1, PS2 and APOE [139] [140] [141] [142] [143] [144] [145] . APP, PS1 and PS2 gene mutations are all associated with familial forms of AD [139, 140, [143] [144] [145] [146] , whereas the APOE 4 allele is associated with sporadic AD and CAA [141, [147] [148] [149] . Screening for APP, PS1 and PS2 mutations can help to detect family members at risk for AD [146] . For sporadic AD, APOE genotyping is often determined in demented patients but its diagnostic value is limited [150] . APOE 4 carriers develop clinical and neuropathological changes of AD usually earlier than non-carriers [150] . Age and gender, thereby, additionally modify its effects on the neuropathological pattern of neurofibrillary tangle and senile plaque distribution [151] . 
